Conavi Medical Reports Fiscal 2024 Financial Results and Operational Highlights – Completed US$7.7 million financing and reverse takeover to take Company public – Chinese partner achieved regulatory approval, setting stage for royalty stream and triggering US$5.9 million...

Conavi Medical to Participate in the MedInvest MedTech, AI & Digital Health Conference – Marks first time as a public company that Conavi is presenting at an investor event – – Live webcast presentation on Wednesday, December 11ᵗʰ at 3:35 p.m. ET – TORONTO, Dec. 10, 2024 (GLOBE...

China's NMPA Approves EOM’s Coronary Imaging System Based on Conavi Medical’s IP – Approval triggers fourth and final US$5.9 million milestone payment to Conavi Medical, which it will use to extinguish the promissory note owed by it to EOM – – Conavi Medical eligible to receive...

JACC: Cardiovascular Interventions Publishes Peer-Reviewed Article on Emerging Hybrid Intracoronary Imaging Technologies – Conavi Medical’s Novasight Hybrid™ System is the first technology to combine both IVUS and OCT to enable simultaneous and co-registered imaging of coronary arteries – – Company showcasing its...

Conavi Medical Corp. Engages ICP Securities Inc. for Automated Market Making Services TORONTO, Oct. 22, 2024 (GLOBE NEWSWIRE) -- CONAVI MEDICAL CORP. (TSXV: CNVI) (“CONAVI MEDICAL” or the “Company”), a commercial stage company focused on designing, manufacturing, and marketing...